ATP-Citrate Synthase Phospho-Ser455 (ACLY pS455) Antibody

Este producto es parte de ACLY - ATP-Citrate Synthase
Product Graph
221€ (50 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
ATP-Citrate Synthase Phospho-Ser455 (ACLY pS455) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx329910
tested applications
ELISA, WB, IHC

Description

ACLY (pS455) Antibody is a Rabbit Polyclonal against ACLY (pS455).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
ATP-Citrate Synthase Phospho-Ser455 (ACLY pS455)
Host
Rabbit
Reactivity
Human, Mouse, Rat, Monkey
Assay Data
Modification: Phosphorylation // Target Modification: Ser455
Recommended Dilution
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/300. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified by affinity chromatography.
Size 1
50 µg
Size 2
100 µg
Form
Liquid
Tested Applications
ELISA, WB, IHC
Buffer
PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P53396
Gene ID
47
Alias
ACL,ATPCL,CLATP
Background
Antibody anti-ACLY
Status
RUO

Descripción

ATP-Citrate Synthase (ACLY) is a cytoplasmic enzyme that catalyzes the conversion of citrate and CoA into acetyl-CoA and oxaloacetate, a reaction powered by ATP hydrolysis. ACLY is a central player in cellular metabolism, linking energy production in the mitochondria with fatty acid and cholesterol biosynthesis. Acetyl-CoA generated by ACLY serves as a precursor for lipid synthesis and is essential for protein acetylation, including histone acetylation, which regulates gene expression. ACLY activity is upregulated in cancer cells to support rapid cell proliferation and metabolic reprogramming, making it a target for cancer therapy. Dysregulation of ACLY is also associated with metabolic diseases such as obesity, insulin resistance, and hyperlipidemia.

Related Products

EH1580

Human ACLY (ATP-citRate synthase) ELISA Kit

Ver Producto
EH5000

Human AcLys (anti acetylated Lysin antibodies) ELISA Kit

Ver Producto
FNab00687

ACLY antibody

Ver Producto